Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Dyanavel XR
(United States) [Available] ,Evekeo
(United States) [Available] ,Adzenys XR-ODT
(United States) [Available]Synonyms :
amphetamine
Class :
CNS Stimulant agents
Brand Name :
Dyanavel XR
(United States) [Available] ,Evekeo
(United States) [Available] ,Adzenys XR-ODT
(United States) [Available]Synonyms :
amphetamine
Class :
CNS Stimulant agents
Dosage Forms & Strengths
Suspension extended release, Oral:
1.25 mg/ml (450 ml)
2.5 mg/ml (464 ml)
Tablet, Oral:
5 mg
10 mg
Tablet chewable extended release, Oral:
5 mg
10 mg
15 mg
20 mg
Tablet disintegrating, Oral:
5 mg
10 mg
15 mg
20 mg
Tablet extended release disintegrating, Oral:
3.1 mg
6.3 mg
9.4 mg
12.5 mg
15.7 mg
18.8 mg
Note: prefer lower effective dose administration
Attention Deficit Hyperactivity Disorder (ADHD)
ER orally disintegrating tablet/oral suspension:
12.5
mg
Orally
once a day
Dyanavel XR oral suspension:
Initial dose: 2.5 or 5 mg orally once daily morning
Increase up to 10 mg per day every day for 4 to 7 days until the required response is achieved (Do not exceed 20 mg/day)
Immediate release:
Initial dose: 5 mg orally disintegrating tablet once or twice a day
Increase 5 mg at weekly intervals until the required response is achieved (preferred to be given in intervals of 4 to 6 hours at the early morning)
Immediate release::
5 - 60
mg
once a day
in divided doses
Immediate-release:
5 - 10
mg
Orally
every day
30 to 60 mins before meals (Do not exceed 30 mg/day)
Suspension extended release, Oral:
1.25 mg/ml (450 ml)
2.5 mg/ml (464 ml)
Tablet, Oral:
5 mg
10 mg
Tablet chewable extended release, Oral:
5 mg
10 mg
15 mg
20 mg
Tablet disintegrating, Oral:
5 mg
10 mg
15 mg
20 mg
Tablet extended release disintegrating, Oral:
3.1 mg
6.3 mg
9.4 mg
12.5 mg
15.7 mg
18.8 mg
Note: prefer lower effective dose administration
Attention Deficit Hyperactivity Disorder (ADHD)
ER orally disintegrating tablet/oral suspension: :
For >6 years: 6.3 mg orally once daily (Increase 3.1 mg or 6.3 mg at weekly intervals) (NMT 12.5 mg/day)
Or
2.5 or 5 mg oral suspension once every morning, increase gradually to 10 mg/day every 4 to 7 days until the required response is obtained (NMT 20 mg/day)
Immediate release:
For 3 to 5 years: 2.5 mg initially orally disintegrating tablets once daily, increase gradually 2.5 mg every week until required response is obtained
Maintain 5 to 40 mg/day in divided doses after initial recovery
For >6 years: 5 mg initially orally disintegrating tablets once daily, increase gradually 2.5 mg every week until required response is obtained
Maintain 5 to 40 mg/day in divided doses after initial recovery
Immediate release::
For 6 to 11 years: 5 mg/day initially in divided doses, increase 5 mg/day weekly until required response achieved
For >12 years: 10 mg/day initially in divided doses, increase 10 mg/day weekly until required response achieved
Maintain dose between 5 to 60 mg/day once a first response is achieved (max. 60 mg/day)
Immediate release::
For >12 years: 5 to 10 mg orally 30 to 60 mins before meals (Do not exceed 30 mg/day)
Refer to adult dosing
Initiate at lower doses
It may diminish the excretion when combined with alkalinizing agents.
It may diminish the excretion when combined with alkalinizing agents.
It may diminish the excretion when combined with alkalinizing agents.
It may diminish the excretion when combined with alkalinizing agents.
It may diminish the excretion when combined with alkalinizing agents.
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may increase the risk of adverse effects when combined
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
CNS depressants increase the effect of orphenadrine
Proton Pump inhibitors may increase the absorption of amphetamine
Proton Pump inhibitors may increase the absorption of amphetamine
Proton Pump inhibitors may increase the absorption of amphetamine
Proton Pump inhibitors may increase the absorption of amphetamine
Proton Pump inhibitors may increase the absorption of amphetamine
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
May have an increased serotonergic effect when combined with Serotonergic Agents
may have an increased cardiotoxic effect when combined with quinolones
may have an increased cardiotoxic effect when combined with quinolones
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may decrease the antihypertensive effect when combined with antihypertensive agents
amphetamines: they may diminish the serum concentration of urinary acidifying agents
amphetamines: they may diminish the serum concentration of urinary acidifying agents
amphetamines: they may diminish the serum concentration of urinary acidifying agents
it may diminish the metabolism when combined with ciclesonide
The effectiveness of guanoxan's antihypertensive properties could be diminished by the presence of amphetamine
When used with amphetamine, levobetaxolol's therapeutic effectiveness may be diminished
The potential for elevated risk or seriousness of hypertension may arise when amphetamine is utilized concurrently with antipyrine
amphetamine has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
Combining tegafur with amphetamine can reduce tegafur’s metabolism
amphetamines: they may increase the analgesic effect of opioid drugs
amphetamines: they may increase the analgesic effect of opioid drugs
amphetamines: they may increase the analgesic effect of opioid drugs
amphetamines: they may increase the analgesic effect of opioid drugs
amphetamines: they may increase the analgesic effect of mu-opioid receptor agonists
amphetamines: they may increase the analgesic effect of mu-opioid receptor agonists
When amphetamine is used together with hexoprenaline, the potential for hypertension to occur may be elevated
When domeperidone and amphetamine is used together, this leads to reduction in the domeperidone’s metabolism
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
When amphetamine is used together with abediterol, this leads to enhanced risk or seriousness of hypertension
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of amphetamine which leads to increased level of serum
When amphetamine is used together with aluminium phosphate, this leads to a reduction in the concentration serum of amphetamine
When amphetamine is used together with bismuth subnitrate, this leads to an enhanced concentration serum of amphetamine
amphetamine leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
amphetamine leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
amphetamine leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
amphetamine leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
amphetamine: it may increase the risk of adverse effects of oxtriphylline
amphetamine: it may decreased the serum concentration of CNS depressants
amphetamine: it may decreased the serum concentration of CNS depressants
amphetamine: it may decreased the serum concentration of CNS depressants
amphetamine: it may decreased the serum concentration of CNS depressants
amphetamine: it may decreased the serum concentration of CNS depressants
combining amphetamine with dapoxetine may increase the intensity of serotonin syndrome
the chances of serotonin syndrome may be increased when amphetamine is combined with zimelidine
the risk or extent of tachycardia can be raised when amphetamine is combined with clidinium
amphetamine's serum concentration may increase when combined with almasilate
When amphetamine is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may increase the analgesic effects of opioid agonists
may decrease the antihypertensive effects
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
may increase the risk or severity of hypertension when combined
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
metyrosine: they may increase the sedative effect of CNS stimulants
pegvisomant: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
an increase in the severity of hypertension may be seen when amphetamine is administered with kebuzone
the therapeutic effect of amphetamine may be increased
the risk of hypertension may be increased
the analgesic activity of meptazinol may be increased
When amphetamine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
amphetamine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Frequency defined:
>10%
Headache
Decreased appetite
Abdominal pain
Emotional lability
Allergic rhinitis
Epistaxis
Frequency not defined
Acute myocardial infarction
Cardiomyopathy
Palpitations
Tachycardia
Skin rash
Stevens johnson syndrome
Toxic epidermal necrolysis
Weight loss
Change in libido
Anorexia
Diarrhea
Unpleasant taste
Impotence
Prolonged erection
Aggressive behavior
Depression
Dizziness
Drug abuse
Drug dependence
Dysphoria
euphoria
headache
restlessness
psychosis
overstimulation
talkativeness
Postmarketing
Angioedema
Hepatotoxicity
Delusion
Hallucination
Suicidal ideation
Pregnancy consideration: Studies reported an increased risk of premature birth and low birth weight during pregnancy.
Lactation: Amphetamine can be excreted in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: Amphetamine
Pronounced: amphetamine
Why do we use amphetamine?
Amphetamine is used to treat sleep apnea, narcolepsy, and other conditions related to daytime sleepiness. It is used for ADHD and weight loss.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
